Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer

March 29, 2017

Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.

The results of an open-label pilot study comparing combinations of anti-PD1 (nivolumab) alone, or in combination with either anti-CTLA-4 (ipilimumab) or anti-VEGF (bevacizumab) therapies, revealed "promising clinical activities" in MRCC patients. Results will be presented April 4 in a poster session at the annual meeting of the American Association of Cancer Research in Washington, D.C.

In this study of 60 patients, 44 were "evaluable" for clinical responses for at least 12 weeks. The combination of nivolumab plus bevacizumab, a drug that inhibits tumor blood vessel formation, appeared to result in the highest response rate in the study, with 53 percent (10 of 19) of patients experiencing either a complete or partial response. This group also reported higher levels of adverse effects, but a substantial percentage was due to bevacizumab-related hypertension easily controlled by standard medications.

"This trial was aimed at getting pre- and post- treatment samples to evaluate immune responses in patients in order to understand potential mechanisms of response and resistance that may be common or unique," said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology. "Immune and molecular correlative studies may allow us to identify novel biomarkers that can be used for correlation with clinical outcomes in MRCC patients."

Immune checkpoint blockade, including anti-CTLA-4 and anti-PD1 as monotherapies, have been known to have clinical activity against MRCC but with relatively low clinical response rates. Bevacizumab is a standard therapy for MRCC but also has a low response rate. The researchers hypothesized that combination therapies could lead to measurable immunological changes and improved clinical activity.

The pre-surgical/pre-biopsy trial included adult patients with MRCC who had no prior treatment with ipilimumab, nivolumab or bevacizumab. The patients were enrolled and stratified by planned surgical procedure or biopsy and randomized to receive nivolumab alone, nivolumab plus bevacizumab, or nivolumab plus ipilimumab. The therapies were followed by surgical removal of tumors or post-treatment biopsies. Patients were then placed on nivolumab maintenance therapy for up to two years depending on and/or treatment intolerance. Pre- and post-treatment blood and tumor samples were obtained for monitoring of immune and molecular correlates to clinical activities. Patients were followed for a median duration of 17 weeks ranging from three to 85 weeks as of Dec. 16, 2016.

"Out of 60 patients treated, 44 were evaluable for clinical responses post-treatment and/or procedures," said Jianjun Gao, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology. "We observed a response rate of 53 percent for patients treated with nivolumab plus bevacizumab."

The study also revealed a 38 percent response rate for those who received nivolumab plus ipilimumab, while receiving nivolumab monotherapy had a 42 percent response rate and treatment was generally well tolerated with mostly grade 1 or 2 adverse events. Grade 3 or higher toxicities were 19 percent for nivolumab alone, 41 percent for nivolumab plus bevacizumab, and 27 percent in the nivolumab plus ipilimumab group."

Study findings showed that the patient group receiving nivolumab alone had a stable disease rate of 33 percent with 25 percent experiencing disease progression. Patients receiving nivolumab plus bevacizumab had a 16 percent stable disease and disease progression rates, while 16 percent of participants withdrew from the study. Of those who received nivolumab plus ipilimumab, 8 percent had stable disease rates,38 percent experienced disease progression and 15 percent withdrew from the trial.

"These findings are significant since a signal to indicate efficacy for the nivolumab plus arm could provide data to design a larger study," said Sharma.

Explore further: Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Related Stories

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

April 21, 2015
Giving the two immunotherapies ipilimumab and nivolumab simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment, according to phase II clinical ...

Nivolumab immunotherapy helps patients with advanced bladder cancer

June 5, 2016
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to ...

Researchers test safety of Nivolumab in kidney cancer

June 3, 2013
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with ...

ASCO: combo antibody therapy effective for melanoma

May 17, 2013
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in advance of the annual ...

Two-drug immunotherapy deemed safe for lung cancer patients, study shows

June 2, 2016
Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that ...

Study provides path for new immunotherapy approaches to prostate cancer

March 27, 2017
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.